AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06350851 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological samples collection (blood drawing + feces)
Description: Blood and feces samples will be collected from each volunteer.
Study NCT05922176 — intervention group
Intervention type: OTHER
Intervention: Evaluation of clinical indicators, Sample collection before& after immunotherapy
Description: A. Evaluation of clinical indicators before immunotherapy~1. Symptom Scale for Rhinitis: Total Nasal Symptom Score (TNSS), Rhnitis Quality of Life Questionnaire(RQLQ)~2. American house dust mite-specific immunogloblin G4 (sIgG4)~3. American house dust mite-specific immunogloblin E (sIgE)~B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~C. Evaluation of clinical indicators 4 to 6 months after immunotherapy~: Treatment is performed for about 4 months, and the progress of treatment is evaluated through the evaluation of the following clinical indicators.~same as examination in 'A'~D. Sample collection after 4 to 6 months of immunotherapy same as examination in 'B'
Study NCT05922176 — intervention group
Intervention type: OTHER
Intervention: Sample collection before& after immunotherapy
Description: B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~D. Sample collection after 4 to 6 months of immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)
Study NCT06651905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The patients were given 0.5 mcg /kg dexmedetomidine over 10 min via syringe pump, followed by 0.2-0.7 mcg/kg/hour until the end of intubation according to hemodynamics.
Study NCT06651905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Superior laryngeal nerve block
Description: The patients received an airway nerve block through bilateral superior laryngeal nerve block and trans-tracheal injection for recurrent laryngeal nerve.
Study NCT06654180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology
Description: Orthokeratology is to a rigid contact lens with reverse design to flat the central cornea to correct the myopia, which is to use at night during sleep; DIMS and SVS are both spectacles to wear at daytime; DIMS has many tiny lenses at peripheral of the big lenses to make the peripheral retina myopic defocus during the daytime; SVS has only one focus while DIMS has many focuses made by the tiny segments lenses around the peripheral vision fields; DISK is a soft contact lens with peripheral myopic power design to make the myopic eyes defocus at peripheral during the daytime.
Study NCT06654180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: defocus-incorporated multiple segment lenses (DIMS) spectacles
Description: It is the special lenses with peripheral lots of tiny segments of plus lenses around the center
Study NCT06654180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISK
Description: SVS
Study NCT06654180 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single-focus spectacles
Description: Myopic Glasses with mono-focus in each eye
Study NCT06654934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 8 weeks, 5 mg/day for 4 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 2485 mg).
Study NCT06654934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 14 weeks, 5 mg/day for 24 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 3605 mg).
Study NCT05282277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol
Description: Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
Study NCT05282277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized Progesterone
Description: Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
Study NCT05282277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo Patch
Description: Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
Study NCT05282277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raclopride C11
Description: All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.
Study NCT05395104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup for oral administration
Study NCT05395104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Liquid for intravenous infusion
Study NCT03733067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Double-blind, placebo-controlled, intra-patient dose-escalation trial of abatacept for treating cytopenia in CTLA4 deficiency. Abatacept or placebo will be administered for 3 doses over 30 days, followed by 5 more months of administration at double the initial dose. If the participant s hematologic parameters normalize at Day 120 or onwards, the investigator may taper or discontinue concomitant medications aimed at treating cytopenia.
Study NCT03733067 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
Study NCT06493682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental (Motivational Interviews)
Description: Monitoring 'behaviour of healthcare demand procrastination, health beliefs regarding cervical cancer screenings, and screening participation' with motivational interviewing
Study NCT06015451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-symptom threshold exercise
Description: Aerob exercise at an intensity just below the intensity that provokes symptom exacerbation.
Study NCT06246708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help app with information for grieving Syrian Refugees
Description: This study explores a self-help app for grieving Syrian refugees in Switzerland, featuring five chapters on grief, resources, space, negative thoughts, and future self-help. The Arabic app includes psychoeducational content, audio exercises, and videos. Users personalize it, save favorites, and set reminders. Tailored for Arabic-speaking refugees, it's accessible on iOS and Android, without invasive components. Participants complete one weekly chapter over five weeks. Data input is stored without manipulation. Accessible data includes completed chapters, subchapters, and feedback. The app promotes self-help, respecting cultural nuances for user engagement.
Study NCT06246708 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list
Description: Participants in the wait-list control group, receive access to the same intervention described above after a waiting period of 5 weeks.
Study NCT04866654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML
Description: Nivolumab, 100 mg, 10 mg/ml
Study NCT06134206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trans-burr hole ultrasound
Description: All ultrasound examinations were conducted alongside the routine postoperative CT scan between 3-7 days postoperatively. To minimize potential influences of the patient's head position on the distribution and thickness of the subdural fluid, we first carried out the CT scan with the patient and their head in a supine position. Immediately after the CT scan, the patient remained on the same examination bed, and burr hole ultrasound was performed in the identical supine position. The burr hole was centered in the image, with the outer table surrounding the burr hole displayed as a horizontal line. The content of the burr hole could be differentiated by its higher echogenicity from the subdural residual hematoma or residual fluid. The brain's surface and overlying leptomeninges, however, displayed higher echogenicity compared to the subdural fluid. The subdural hematoma's thickness was measured at its maximum extent.
Study NCT06059651 — intervention group
Intervention type: PROCEDURE
Intervention: Metabolic & Bariatric Surgery
Description: Roux-en-Y metabolic and bariatric surgery
Study NCT04617756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients receiving neoadjuvant therapy before radical nephrectomy
Description: Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
Study NCT06431009 — intervention group
Intervention type: OTHER
Intervention: Treatment-as-usual
Description: Patients will be treated and followed according to normal clinical treatment guidelines at the local psychiatric hospitals, which will not be affected by participation in the RMS cohort.
Study NCT05161832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nocebo
Description: Nocebo ultrasound with diagnosis of a fake shoulder cuff injury.
Study NCT05161832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo ultrasound with no diagnosis of injury.
Study NCT04536454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FPyGal
Description: Radiotracer for PET-imaging
Study NCT05620043 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sculptra
Description: Biostimulator
Study NCT05620043 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiesse Plus
Description: Semi-permanent filler
Study NCT06493877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retraining program after thoracic surgery
Description: An effort retraining program will be carried out, with respiratory physiotherapy, muscle strengthening exercises and aerobic exercise, for four weeks, every other day, with a duration of 75 minutes each session. Both the control and experimental groups will receive a common treatment: Muscle strength and aerobic resistance exercises will be performed following the F.I.T.T principle, working the main muscle groups against resistance (between 40% and 60% RM) performing three sets of ten repetitions of each one. It will begin with a warm-up and then a cool down with stretching. We will apply respiratory physiotherapy techniques to promote ventilation and drainage of secretions.~Next, the aerobic work is carried out according to the assigned group: treadmill with a positive slope (experimental group), treadmill with a negative slope (control 1) or cycle ergometer (group 2).
Study NCT06493877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retraining program after thoracic surgery
Description: An effort retraining program will be carried out, with respiratory physiotherapy, muscle strengthening exercises and aerobic exercise, for four weeks, every other day, with a duration of 75 minutes each session. Both the control and experimental groups will receive a common treatment: Muscle strength and aerobic resistance exercises will be performed following the F.I.T.T principle, working the main muscle groups against resistance (between 40% and 60% RM) performing three sets of ten repetitions of each one. It will begin with a warm-up and then a cool down with stretching. We will apply respiratory physiotherapy techniques to promote ventilation and drainage of secretions.~Next, the aerobic work is carried out according to the assigned group: treadmill with a positive slope (experimental group), treadmill with a negative slope (control 1) or cycle ergometer (group 2).
Study NCT05863520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zones of Regulation
Description: ZOR is rooted in CBT principles and uses a metacognitive framework to increase awareness of feelings and to build regulation, prosocial skills, and overall wellness.
Study NCT05863520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facing Your Fears - School Based
Description: FYF-SB is a CBT program for managing anxiety in autistic youth.
Study NCT05344768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Moderate intensity aerobic exercise training will be applied.
Study NCT05344768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity interval exercise training
Description: High-intensity interval exercise training will be applied.
Study NCT05344768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercise training
Description: resistance exercise training will be applied
Study NCT06430944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placing a hip spica cast for patients with femur fractures
Description: Placing a hip spica cast for patients with femur fractures. These hip spicas are made for each patient to stabilize the fracture in pediatric patients
Study NCT06430944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placing a hip spica cast for patients with femur fractures
Description: Placing a hip spica cast for patients with femur fractures. These hip spicas are made for each patient to stabilize the fracture in pediatric patients
Study NCT04721821 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: Patients who received Tofacitinib for RA
Study NCT04289740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals
Description: Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period
Study NCT04289740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure plus same number of sessions as the experimental intervention.
Description: The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
Study NCT05794750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104 injection
Description: Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
Study NCT05794750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME surgery
Description: Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
Study NCT05794750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
Study NCT05794750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
Study NCT05216900 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: The study examines the delivery NART.~In case of neoadjuvant chemotherapy, RT will start 6-8 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions per week, or a biologically equivalent dose will be applied.~A mastectomy and a direct breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment. Breast reconstruction can be separated in the types of reconstruction, either reconstruction with a silicone implant or with only autologous tissue, of which the most common flap used is the Deep Inferior Epigastric Perforator (DIEP) flap.
Study NCT06257992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: 3 treatments of dry needling to inactivate all active trigger points found in patient's cervical muscles.
Study NCT06257992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretch
Description: 3 treatments of stretch applied to all cervical muscles that present active trigger points in patient's cervical muscles.
Study NCT05635916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Adductor canal block with injection of 10cc 13.3% liposomal bupivacaine combined with 10cc 0.50% bupivacaine within one hour following surgery
Study NCT05635916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Adductor canal block with injection of 20cc 0.5% bupivacaine within one hour following surgery
Study NCT06396650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based training
Description: 1. If the participant shows instability in any specific perturbation directions or with excessive body swaying, the participant will practice walking with a cellphone strapped on the chest in-home training. A cellphone App will detect potential excessive body swaying in any directions and prompt the participant with real time audio-visual feedback to reduce sway in the specific directions.~2. If the subject is diagnosed with collapse-related vertical instability, lower-limb muscle strengthening will be emphasized in the training. The subject may work out with a Shuttle Mini-Press, AB Squat machine, Rowing machine, or Upright Row-n-Ride. The Investigators will select one machine appropriate for the subject to take home. The exercise will be 3-5 sets a day and about 15 repetitions per set. In the beginning, the exercise can be slower and with fewer repetitions based on the subject's capability. As the subject progresses, the subject may change from one exercise machine to another.
Study NCT06396650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lab-based training
Description: In the weekly lab-based training session, the subject will do individualized training using the sliding stepping trainer, with a focus on the direction the subject showed higher risks of falling, as identified in the initial assessment. The sliding stepping trainer will generate perturbations of the footplates in those identified risky directions during stepping.
Study NCT05729568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teropavimab
Description: Administered intravenously
Study NCT06654115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wireless Physiologic Monitoring
Description: YHE® BP Doctor Pro Blood Pressure Smartwatch, which is a commericially available device. The device can monitor heart rate, blood pressure and saturation.
Study NCT06586710 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment activation of interferon pathway
Description: * Peripheral blood collection (as part of routine blood draws) on which interferon signature will be performed at the time of enrollment and in case of remission and/or any renal flare.~* Renal biopsies (routinely performed for diagnostic purposes and during clinical follow-up) on which Myxovirus resistance protein 1 (MXA) expression and histopathologic characterization will be assessed.~* Collection of clinical and laboratory data from routine visits performed at baseline and 3, 6, 12, and 24 months (or last available visit) after the renal biopsy was performed.
Study NCT06603584 — intervention group
Intervention type: RADIATION
Intervention: Chest x- Rays
Description: prebronchial Thicknening - Right upper lobe Patches suggesting Aspiration -Collapsing lobe
Study NCT05729568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinlirvimab
Description: Administered intravenously
Study NCT05729568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Tablet
Description: Administered orally